

Amendments to the Specification:

Please replace Table I on page 20 of the present specification with the following Table I:

| Table: 1 Combined therapy induces tumour-specific immunity ^a | | | | | |
|---|-----------------------------------|-------------------|------------------|---|---|
| Tumour cells Injected | Mice challenged with tumour cells | Challenge dose | Tumour incidence | Tumour onset (days) tumour size <0.2 cm | Time of sacrifice (days) ^b (tumour size <1.0 cm) |
| EL4 | EL4 | 1X10 ⁴ | 0/6 | - | - |
| | | 1X10 ⁵ | 0/6 | - | - |
| | | 1X10 ⁷ | 0/6 | - | - |
| | LLC | 1X10 ⁴ | 5/5 | 16-24 | 35±4.2 |
| | | 1X10 ⁵ | 5/5 | 14-20 | 30±5.1 |
| | | 1X10 ⁷ | 5/5 | 14-19 | 29±4.3 |
| LLC | LLC | 1X10 ⁴ | 0/6 | - | - |
| | | 1X10 ⁵ | 0/6 | - | - |
| | | 1X10 ⁷ | 1/6 | - | 29 |
| | EL-4 | 1X10 ⁴ | 5/5 | 18-26 | 38±6.1 |
| | | 1X10 ⁵ | 5/5 | 16-22 | 36±6.1 |
| | | 1X10 ⁷ | 5/5 | 16-24 | 33±4.5 |

^a Tumors were established with EL4 or LLC tumor cells and B7.1 DNA injected intratumorally, Twenty-four hours later, DMXAA was administered i.p. and after 21 days animals were challenged.

^b Values represent means ±SD, calculated from 5 or 6 mice per group.